u/happy123z

Reddit r/stocks
· tracked since Feb 2026
Calls
3
Win Rate
100.0%
return
+112.3%
Calls 3 1 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 0
Win Rate 100% Long 3 Short 0
Win Rate
7d 67%
30d 100%
90d 100%
Average Return +112.3% Long Return +112.3% Short Return -
Average Return
7d +0.5%
30d +24.1%
90d +16.0%
Visual Insights Log in to see more
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Feb 03
$6.33
+34.0%
Long IBRX on results, leadership, catalysts
The author is invested in IBRX alongside SLS and DRTS, citing great results, good leadership and existing approvals. Scheduled catalysts are the reason for holding, with plans to move money as events occur. The main risk is the author's newness and the sector's reputation.
Pharma & Biotech
Long
Feb 03
$6.85
+127.7%
Long DRTS on results, leadership, catalysts
The author holds DRTS as one of three biotech picks, citing great results, good leadership and some approvals already in place. Multiple scheduled catalysts are the stated reason for holding and rotating capital between the names. The main risk is the author's inexperience and the sector's poor reputation.
MedTech
Long
Feb 03
$4.16
+175.2%
Long SLS on possible early trial success
The author is invested in SLS, citing great results, good leadership and multiple scheduled catalysts, including a possible early end to a trial that appears to be a huge success. The stated catalyst is the potential early trial termination announcement, which the author does not want to miss. The main risk is the author's own admission of being a new investor in a sector with a bad reputation.
Pharma & Biotech
Showing 3 of 3 calls · sorted by mentions

u/happy123z has 3 trade ideas tracked on Buzzberg across 3 tickers since February 2026. Most covered: IBRX, SLS, DRTS.

Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology